Group 1 - The core viewpoint of the article highlights the significant stock price increase of Basilea Pharmaceutica (02616), which rose over 9% in early trading and is currently up 6.11% at HKD 7.29, with a trading volume of HKD 12.048 million [1] - GIC has increased its stake in Basilea Pharmaceutica to 6% as of October 13, marking its second substantial purchase in less than two months, having previously acquired 80.4 million shares for over HKD 630 million on August 18 [1] - The European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Sugliatinib as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) who have PD-L1 expression ≥1% and have not progressed after platinum-based chemoradiotherapy [1]

另外，基石药业即将于10月19日在2025年欧洲肿瘤内科学会年会上，公布其全球首创的PD- 1/VEGF/CTLA-4三特异性抗体CS2009在约70例患者中的初步临床数据，这将是该类靶点药物的全球首 次临床数据发表，备受行业瞩目。与此同时，其另一款ADC药物CS5001的临床方案也将同步披露。 新加坡政府投资公司GIC Private Limited持续看好并加码基石药业(02616)。根据香港联交所最新资料， GIC于10月13日披露再度增持基石药业，持股数达88,618,000，持股比例达到6%，彰显其长期信心。较 此前权益披露新增持股超过820万股，其10月13日单日增持股票部分平均成本6.9576港币/股。 值得注意的是，这已是GIC在不到两个月内的第二次大举增持——此前8月18日，GIC曾大手笔增持基石 药业8040万股股份，耗资超6.3亿港元。 ...

值得注意的是，这已是GIC在不到两个月内的第二次大举增持——此前8月18日，GIC曾大手笔增持基石 药业8040万股股份，耗资超6.3亿港元。 另外，基石药业即将于10月19日在2025年欧洲肿瘤内科学会年会上，公布其全球首创的PD- 1/VEGF/CTLA-4三特异性抗体CS2009在约70例患者中的初步临床数据，这将是该类靶点药物的全球首 次临床数据发表，备受行业瞩目。与此同时，其另一款ADC药物CS5001的临床方案也将同步披露。 智通财经APP获悉，新加坡政府投资公司GIC Private Limited持续看好并加码基石药业(02616)。根据香 港联交所最新资料，GIC于10月13日披露再度增持基石药业，持股数达88,618,000，持股比例达到6%， 彰显其长期信心。较此前权益披露新增持股超过820万股，其10月13日单日增持股票部分平均成本 6.9576港币/股。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前 瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任 何前瞻性陳述及預料之外的事件。請細閱本公告，並理解我們的實際未來業績或表現可能與預期有 重大差異。本公告中有關我們或任何董事及╱或本公司的意向的陳述或提述乃於本公告刊發日期作 出。任何該等意向均可能因未來發展而出現變動。 CStonePharmaceuticals 基石藥業 ( 於開曼群島註冊成立的有限公司 ) (股份代號：2616) 自願 公告 基石藥業舒格利單抗再獲歐洲藥品管理局人用藥品委員會積極意見，有望在歐洲同時覆蓋III期 和IV期非小細胞肺癌適應症 本公告乃由基石藥業(「本公司」連同其附屬公司統稱(「本集團」或「基石藥業」)自願作出， 以使本公司股東及潛在投資者瞭解本集團的最新業務發展。 ……………………………………… ...

格隆汇10月17日丨根据联交所最新权益披露资料显示，2025年10月13日，基石药业-B(02616.HK)获GIC Private Limited在场内以每股均价6.9576港元增持 226.1万股，涉资约1573.11万港元。 增持后，GIC Private Limited最新持股数目为8861.8万股，持股比例由5.85%上升至6.00%。 | 股份代號: | 02616 | | --- | --- | | 上市法國名稱: | 基石藥業 - B | | 日期 (日 / 月 / 年): | 17/09/2025 - 17/10/2025 | | 表格序號 | 大股東/董事/最高行政人員名稱作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | | ( 請參閱上述 * 註 | 有投票權股 (日 / 月 / 年) | | | | | | | | | 份自分比 | | | | | | | | | ( %) ...

香港联交所最新资料显示，10月13日，GIC Private Limited增持基石药业(02616)226.1万股，每股作价 6.9576港元，总金额约为1573.11万港元。增持后最新持股数目为8861.8万股，持股比例为6%。 ...

智通财经APP获悉，香港联交所最新资料显示，10月13日，GIC Private Limited增持基石药业 (02616)226.1万股，每股作价6.9576港元，总金额约为1573.11万港元。增持后最新持股数目为8861.8万 股，持股比例为6%。 ...

Core Viewpoint - 基石药业-B's stock price increased by 3.09% to 7.01 HKD, with a trading volume of 37.03 million HKD, following the announcement of key clinical data to be presented at the upcoming ESMO annual meeting in 2025 [1] Group 1: Clinical Pipeline Updates - 基石药业's core clinical pipeline includes CS2009, a PD-1/VEGF/CTLA-4 tri-specific antibody, and CS5001, an ROR1 antibody-drug conjugate (ADC) [1] - The I期 dose-escalation clinical data summary for CS2009 has been published on the ESMO website, covering data from 9 patients as of May 8, 2025 [1] - At the ESMO conference, 基石药业 will present preliminary data from the I期 dose-escalation study of CS2009 involving approximately 70 patients with advanced solid tumors, marking the first known clinical data publication globally for a PD-1/VEGF/CTLA-4 tri-specific antibody [1]

Core Viewpoint - Company shares of Basilea Pharmaceutica (02616) rose over 3%, currently trading at 6.99 HKD with a transaction volume of 15.38 million HKD, following the announcement of key clinical data to be presented at the upcoming ESMO conference in October 2025 [1] Group 1: Clinical Pipeline Updates - Basilea announced that its core clinical pipeline, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), will present preliminary data from an ongoing Phase I dose-escalation study at the ESMO conference [1] - The abstract for CS2009 includes data from 9 patients as of the submission deadline on May 8, 2025, aimed at meeting ESMO's submission requirements [1] - The company will also showcase preliminary data from approximately 70 patients with advanced solid tumors for CS2009 in a poster presentation at the ESMO conference, marking the first known clinical data globally for a PD-1/VEGF/CTLA-4 tri-specific antibody [1] Group 2: Upcoming Events - The 2025 European Society for Medical Oncology (ESMO) annual meeting is scheduled to take place from October 17 to 21, 2025, in Berlin, Germany [1]

Core Viewpoint - The stock of Cornerstone Pharmaceuticals-B (02616) has seen an increase of over 3%, currently trading at 6.99 HKD with a transaction volume of 15.38 million HKD, following the announcement of key clinical data to be presented at the upcoming ESMO conference in 2025 [1] Group 1: Clinical Pipeline Updates - Cornerstone Pharmaceuticals is set to present preliminary data from its core clinical pipeline, specifically the CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody) and CS5001 (a ROR1 antibody-drug conjugate) at the 2025 ESMO annual meeting [1] - The abstract for CS2009 includes data from 9 patients as of the submission deadline on May 8, 2025, fulfilling ESMO's submission requirements [1] - At the ESMO conference, Cornerstone will showcase preliminary data from the I phase dose-escalation study of CS2009 involving approximately 70 patients with advanced solid tumors, marking the first known clinical data presentation globally for a PD-1/VEGF/CTLA-4 tri-specific antibody [1]